Gast ::
| Hauptseite > Publikationsdatenbank > IMG-98. Metabolic response using the PET RANO 1.0 criteria following chemoradiation is associated with an increase in functional connectivity > print |
| Hauptseite > Publikationsdatenbank > IMG-98. Metabolic response using the PET RANO 1.0 criteria following chemoradiation is associated with an increase in functional connectivity > print |
| 001 | 1053912 | ||
| 005 | 20260201102954.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noaf201.1177 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 037 | _ | _ | |a FZJ-2026-01610 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kraft, Manuel |0 P:(DE-Juel1)208037 |b 0 |u fzj |
| 111 | 2 | _ | |a 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies |g SNO / WFNOS 2025 |c Honolulu |d 2025-11-20 - 2025-11-23 |w USA |
| 245 | _ | _ | |a IMG-98. Metabolic response using the PET RANO 1.0 criteria following chemoradiation is associated with an increase in functional connectivity |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1769938183_17679 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a AbstractBACKGROUNDThe emerging field of Cancer Neuroscience suggests intense structural and functional connections between gliomas and the CNS, leading to large-scale network alterations. Resting-state fMRI (rs-fMRI) offers the option to evaluate functional connectivity (FC) within this complex network. For example, recent data suggest that the integrity of FC obtained from single scans in recurrent gliomas is prognostic in terms of overall survival. In the present study, we evaluated in patients with glioma undergoing treatment whether a metabolic response in O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET is also associated with FC improvement using serial rs-fMRI.METHODSForty-five patients with glioma characterized according to the CNS WHO 2021 classification (glioblastoma, n=27; grade 3 or 4 astrocytoma, n=8; grade 2 or 3 oligodendroglioma, n=10), were retrospectively identified. Serial rs-fMRI and FET PET were performed using a 3T hybrid PET/MR scanner before and after chemoradiation (n=27), resection (n=9), or during the treatment-free interval at two time points (n=9). The mean time between scans was 6.0 months. Metabolic response was assessed using the PET RANO 1.0 criteria. FC was assessed by examining the BOLD-activity time course correlations in rs-fMRI within and between seven canonical resting-state networks.RESULTSAt follow-up, FC of brain regions within the limbic resting-state network significantly increased in metabolic responders (n=23) compared to non-responders (n=22) who showed a decrease in FC (p=0.011). In subgroup analyses of the received treatment modality, this change of FC in association with metabolic response was significant only in patients who had received chemoradiation (n=27; p=0.026), whereas in patients who had undergone resection, a similar tendency unveiled (n=9; p=0.053). In contrast, metabolic response was not associated with FC changes in patients during the treatment-free interval (n=9; p=0.459).CONCLUSIONSOur data suggest that FC is restored in metabolic responders following glioma treatment, indicating its predictive potential as imaging marker for response assessment. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Hilgers, Julia |0 P:(DE-Juel1)203564 |b 1 |u fzj |
| 700 | 1 | _ | |a Peplinski, Jana-Marie |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Wollring, Michael |0 P:(DE-Juel1)190394 |b 5 |
| 700 | 1 | _ | |a Stetter, Isabelle |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Fink, Gereon R |0 P:(DE-Juel1)131720 |b 7 |u fzj |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 8 |u fzj |
| 700 | 1 | _ | |a Mottaghy, Felix M |0 P:(DE-Juel1)132318 |b 9 |u fzj |
| 700 | 1 | _ | |a Ciantar, Keith George |0 P:(DE-Juel1)203314 |b 10 |u fzj |
| 700 | 1 | _ | |a Shah, Nadim J |0 P:(DE-Juel1)131794 |b 11 |u fzj |
| 700 | 1 | _ | |a Lohmann, Philipp |0 P:(DE-Juel1)145110 |b 12 |u fzj |
| 700 | 1 | _ | |a Kocher, Martin |0 P:(DE-Juel1)173675 |b 13 |u fzj |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 14 |u fzj |
| 773 | _ | _ | |a 10.1093/neuonc/noaf201.1177 |0 PERI:(DE-600)2094060-9 |y 2025 |g Vol. 27, no. Supplement_5, p. v297 - v297 |x 1523-5866 |
| 856 | 4 | _ | |u https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v297/8319254 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)208037 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)203564 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)132318 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)203314 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)131794 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)145110 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 13 |6 P:(DE-Juel1)173675 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 14 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-11 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 0 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|